Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/43648
Campo DC Valoridioma
dc.contributor.authorRodríguez-Hernández, Juan Lizandroen_US
dc.contributor.authorRodríguez-González, Faynaen_US
dc.contributor.authorRiaño-Ruiz, Martaen_US
dc.contributor.authorMartínez Quintana, Efrénen_US
dc.date.accessioned2018-11-21T16:48:00Z-
dc.date.available2018-11-21T16:48:00Z-
dc.date.issued2018en_US
dc.identifier.issn1747-079Xen_US
dc.identifier.otherWoS-
dc.identifier.urihttp://hdl.handle.net/10553/43648-
dc.description.abstractIntroduction: Hyperuricemia has been associated with cardiovascular risk factors but it remains controversial if uric acid is an independent predictor of cardiac mortality. Methods: A total of 503 CHD patients (457 nonhypoxemic and 46 hypoxemic) and 772 control patients fulfilled inclusion criteria. Demographic, clinical, and analytical data [serum uric acid and 24h urine uric acid levels, N‐terminal pro‐B‐type natriuretic peptide (NT‐pro‐BNP), and C‐reactive‐protein (CRP) concentrations] were studied. Survivals curves to determine cardiac death and arterial thrombosis in CHD patients were also examined. Results: Noncyanotic and cyanotic CHD patients had significant higher serum uric acid concentration (5.2 ± 1.5 vs 4.9 ± 1.3mg/dL, P = .007 and 6.7 ± 2.1 vs 4.9 ± 1.3mg/dL, P < .001, respectively) and gout (1% vs 0%, P = .003 and 4% vs 0%, P < .01, respectively) than the control population. Among CHD patients, hyperuricemic patients were significant older and with overweight, used more diuretics, were more cyanotic and had higher serum creatinine, NT‐pro‐BNP and CRP concentrations than nonhyperuricemic. In the multivariable analysis, the body mass index (BMI) (OR 1.09; 95% CI 1.01–1.18), cyanosis (OR 6.2; 95 CI 1.5–24.6), serum creatinine concentration (OR 49; 95% CI 44–538), and being under diuretic treatment (OR 4.5; 95% CI 1.4–14.5) proved to be risk factors for hyperuricemia in CHD patients. The Kaplan–Meier events free survival curves, during a 5.2 ± 2.7 years follow‐up of up time, showed that hyperuricemic CHD patients had significant higher cardiovascular death (P = .002). However, after applying the Cox regression analysis uric acid levels lost its statistical significance. No significant differences were seen in relation to thrombotic events between CHD patients with and without hyperuricemia. Conclusions: CHD patients, noncyanotic and cyanotic, have higher serum uric acid levels and gout than patients in the general population. BMI, renal insufficiency, cyanosis, and the use of diuretics were risk factor for hyperuricemia among CHD patients.en_US
dc.languageengen_US
dc.publisher1747-079X-
dc.relation.ispartofCongenital Heart Diseaseen_US
dc.sourceCongenital Heart Disease [ISSN 1747-079X], v. 13 (5), p. 655-662, (Septiembre-Octubre 2018)en_US
dc.subject320501 Cardiologíaen_US
dc.subject.otherCardiovascular deathen_US
dc.subject.otherCongenital heart diseaseen_US
dc.subject.otherHyperuricemiaen_US
dc.subject.otherInflammationen_US
dc.subject.otherThrombosisen_US
dc.titleRisk factors for hyperuricemia in congenital heart disease patients and its relation to cardiovascular death.en_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1111/chd.12620-
dc.identifier.scopus85051106997-
dc.identifier.isi000452824600003-
dc.contributor.authorscopusid57193055539-
dc.contributor.authorscopusid24825586600-
dc.contributor.authorscopusid35811047900-
dc.contributor.authorscopusid23485891800-
dc.identifier.eissn1747-0803-
dc.description.lastpage662en_US
dc.identifier.issue5-
dc.description.firstpage655en_US
dc.relation.volume13en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid1386542-
dc.contributor.daisngid648988-
dc.contributor.daisngid5971737-
dc.contributor.daisngid614797-
dc.description.numberofpages8en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Rodriguez-Hernandez, JL-
dc.contributor.wosstandardWOS:Rodriguez-Gonzalez, F-
dc.contributor.wosstandardWOS:Riano-Ruiz, M-
dc.contributor.wosstandardWOS:Martinez-Quintana, E-
dc.date.coverdateSeptiembre 2018en_US
dc.identifier.ulpgces
dc.description.sjr1,036
dc.description.jcr2,036
dc.description.sjrqQ1
dc.description.jcrqQ3
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.fullNameMartínez Quintana, Efrén-
Colección:Artículos
Vista resumida

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.